Your browser doesn't support javascript.
loading
The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL.
Rubinstein, Jeremy D; Breese, Erin H; Krupski, M Christa; O'Brien, Maureen M; Dandoy, Christopher E; Mizukawa, Ben; Khoury, Ruby; Norris, Robin E; Davies, Stella M; Phillips, Christine L.
Afiliação
  • Rubinstein JD; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio; Division of Oncology, Cancer, and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. Electronic address: Jeremy.rubinstein@cchmc.org.
  • Breese EH; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio; Division of Oncology, Cancer, and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
  • Krupski MC; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio; Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
  • O'Brien MM; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio; Division of Oncology, Cancer, and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
  • Dandoy CE; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio; Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
  • Mizukawa B; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio; Division of Oncology, Cancer, and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
  • Khoury R; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio; Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
  • Norris RE; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio; Division of Oncology, Cancer, and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
  • Davies SM; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio; Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
  • Phillips CL; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio; Division of Oncology, Cancer, and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
Transplant Cell Ther ; 29(5): 311.e1-311.e7, 2023 05.
Article em En | MEDLINE | ID: mdl-36809824
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras B / Leucemia-Linfoma Linfoblástico de Células Precursoras / Receptores de Antígenos Quiméricos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Child / Humans Idioma: En Revista: Transplant Cell Ther Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia-Linfoma Linfoblástico de Células Precursoras B / Leucemia-Linfoma Linfoblástico de Células Precursoras / Receptores de Antígenos Quiméricos Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Child / Humans Idioma: En Revista: Transplant Cell Ther Ano de publicação: 2023 Tipo de documento: Article